Prevention of New Sensitization by Specific Immunotherapy
ORIGINAL ARTICLE
Prevention of New Sensitizations by Specific
Immunotherapy in Children With Rhinitis
and/or Asthma Monosensitized to House
Dust Mite
.
1
A Inal,1 DU Alt 1 nt as,
M Yilmaz,1 GB Karakoc,1 SG Kendirli,1 Y Sert demir 2
‘
1
2
Division of Pediatric Allergy and Immunology, Faculty of Medicine, Çukurova University, Adana, Turkey
Department of Biostatistics, Faculty of Medicine, Çukurova University, Adana, Turkey
■ Abstract
Background: Previous studies have suggested that single-allergen–specifi c immunotherapy (SIT) may prevent sensitization to other airborne
allergens in monosensitized children. We aimed to assess the prevention of new sensitizations in monosensitized children treated with
single-allergen SIT injections in comparison with monosensitized patients given appropriate pharmacologic treatment for their disease.
Methods: A total of 147 children with rhinitis and/or asthma monosensitized to house dust mite were studied; 45 patients underwent SIT
with adsorbed extracts and 40 patients underwent SIT with aqueous extracts for 5 years. The control group was comprised of 62 patients
given only pharmacologic treatment for at least 5 years. Skin prick tests, medication scores for rhinitis and asthma, and atopy scores
according to skin prick tests were evaluated at the beginning and after 5 years of treatment.
Results: All groups were comparable in terms of age, sex, and disease characteristics. At the end of 5 years, 64 out of 85 (75.3 % ) in
the SIT group showed no new sensitization, compared to 29 out of 62 children (46.7 % ) in the control group (P = .002). There were no
differences between the SIT subgroups with regard to onset of new sensitization (P = .605). The patients developing new sensitizations
had higher atopy scores (P = .002) and medication scores for both rhinitis (P = .008) and asthma (P = .013) in comparison to patients not
developing new sensitizations after 5 years of SIT.
Conclusion: According to our data, SIT has the potential to prevent the onset of new sensitizations in children with rhinitis and/or asthma
monosensitized to house dust mite.
Key words: Asthma. House dust mite. Immunotherapy. New sensitization. Rhinitis.
■ Resumen
Antecedentes: Estudios previos han sugerido que la inmunoterapia específi ca (ITE) con un único alérgeno puede prevenir la sensibilización
a otros aeroalérgenos en niños monosensibilizados. Nuestro objetivo fue valorar la prevención de nuevas sensibilizaciones en niños
monosensibilizados y tratados con inyecciones de ITE de un sólo alérgeno comparado con pacientes monosensibilizados con un tratamiento
farmacológico apropiado para la enfermedad.
Métodos: Estudiamos a un total de 147 niños con rinitis o asma, monosensibilizados al ácaro del polvo doméstico; 45 pacientes se
sometieron a ITE con extractos adsorbidos y 40 pacientes a ITE con extractos acuosos durante 5 años. El grupo control estaba integrado
por 62 pacientes a quienes sólo se administró tratamiento farmacológico durante cinco años como mínimo. Al inicio del tratamiento y
pasados cinco años, se realizaron evaluaciones de las pruebas cutáneas, de los resultados de los medicamentos para la rinitis y para el
asma, e índices de atopia basados en las pruebas cutáneas.
Resultados: Todos los grupos eran comparables en cuanto a edad, sexo y características de la enfermedad. Transcurridos los cinco años,
64 de los 85 pacientes (75,3 % ) del grupo ITE no presentaban nuevas sensibilizaciones, frente a 29 de los 62 niños (46,7 % ) del grupo
control (P = 0,002). No hubo diferencias entre los subgrupos del tratamiento ITE en cuanto a la aparición de nuevas sensibilizaciones
© 2007 Esmon Publicidad
J Investig Allergol Clin Immunol 2007; Vol. 17(2): 85-91
86
(P = 0,605). Los resultados de atopia (P = .0,002) y de medicamentos para la rinitis (P = 0,008) y el asma (P = 0,013) en los pacientes
que desarrollaron nuevas sensibilizaciones fueron más elevados que los de los pacientes que no presentaron nuevas sensibilizaciones
tras cinco años de ITE.
Conclusión: Según nuestros datos, la ITE puede potencialmente prevenir la aparición de nuevas sensibilizaciones en niños con rinitis o
asma sensibilizados únicamente al ácaro del polvo doméstico.
Palabras clave: Asma. Ácaro del polvo doméstico. Inmunoterapia. Nueva sensibilización. Rinitis.
Introduction
Specific immunotherapy (SIT) was first introduced in
1911 [1]. In 1998, the World Health Organization [2] and the
European Academy of Allergology and Clinical Immunology
(EAACI) [3] affirmed the clinical effectiveness of SIT by
injections or local nasal or sublingual administration in the
management of allergic rhinitis and asthma when standardized
extracts are used in adequate amounts. A meta-analysis
including 54 clinical trials and assessing the efficacy of SIT
in asthma led to the conclusion that SIT significantly reduces
asthma symptoms, medication, and worsening of asthma [4]. SIT
has also proven able to reduce specific bronchial reactivity and
prevent the development of asthma in patients with allergic
rhinitis [5-13]. Whether SIT in monosensitized patients could
have an effect of preventing sensitization to other airborne
allergens has also been investigated [14-16], and it was
recently demonstrated that the reduction of onset of new
sensitization after discontinuation of preseasonal grass pollen
immunotherapy was sustained 12-years later in a prospective
controlled follow-up study [17].
We aimed to investigate the development of new
sensitizations in 147 children with rhinitis and/or asthma
who were monosensitized to house dust mite. One group of
children were treated with SIT injections for 5 years. They were
compared to a parallel group treated with medication only. We
recorded the results of skin prick tests and medication use for
rhinitis and asthma.
M ethods
Pat ient s and St udy Design
The study was planned as a parallel group open study
including patients suffering from allergic rhinitis and/or asthma
who were monosensitized to house dust mite. The patients were
followed from 1995 to 2005 in our department. Inclusion criteria
were as follows: a) age between 6 and16 years; b) a clinical
history of allergic rhinitis and/or mild-to-moderate asthma as
defined by the Global Initiative for Asthma (GINA) report [18],
with symptoms lasting at least 1 year; c) monosensitization
to house dust mite (Dermatophagoides pteronyssinus and/or
Dermatophagoides farinae); d) a positive finding of specific
immunoglobulin (Ig) E to D pteronyssinus and/or D farinae
(Pharmacia CAP system, Pharmacia Diagnostics AB, Uppsala,
Sweden) and/or a positive skin prick test to D pteronyssinus
J Investig Allergol Clin Immunol 2007; Vol. 17(2): 85-91
and/or D farinae (Allergopharma, Reinbeck, Germany); e)
complete follow-up in our department for at least 5 years.
Eighty-five patients underwent SIT and 62 were treated
only with medication. The SIT group was further subdivided
into 2 subgroups of patients who underwent SIT with adsorbed
extracts (SIT-ad) and patients who underwent SIT with aqueous
extracts (SIT-aq). Different SIT regimens were used because
aqueous extracts were used more commonly than adsorbed
extracts in our clinic at the beginning of the study period and in
the following years, the patients on that SIT regimen prefered
to continue with the same extract.
SIT was recommended to all patients after diagnosis,
but patients who did not accept SIT (mainly because of its
cost, inconvenience, or travel difficulties) were treated with
medication only and included as a control group.
Skin Prick Test s
Skin prick tests were performed on the volar surface of
the forarm according to EAACI recommendations [19] at
the beginning and end of SIT. We used a standard panel of
respiratory allergens including mites (D pteronyssinus and
D farinae), grass mix, tree mix, mold mix, Alternaria species,
Cladosporium species, eucalyptus pollen, olive pollen, cat and
dog dander and certain food allergens (milk, egg, cocoa, wheat,
and peanut) (Allergopharma). Histamine hydrogen chloride
10 mg/mL was used as the positive control and physiologic
saline as the negative one. A mean wheal diameter greater
than 3 mm in diameter was considered positive if no
dermographism and/or positivity of the negative control was
recorded. All patients were instructed not to take medications
during the 2 weeks before the test.
SIT
Biologically standardized depot preparations of mite mix
(D pteronyssinus and D farinae) were used for 5 years in the
SIT-ad group. The preparations were aluminium hydroxide
or calcium phosphate adsorbed extracts (Alutard SQ, ALK
Laboratories, Hoersholm, Denmark; NovoHelisen Depot,
Allergopharma; or APSI Retard, Stallergenes, Antony,
France). The ALK preparations were supplied as 4 biologically
standardized allergen concentrations of 100, 1000, 10 000, and
100 000 standard quality units per milliliter; the Stallergenes
preparations were supplied as having indices of reactivity
(IR) of 0.01, 0.1, and 1. The Allergopharma preparations were
© 2007 Esmon Publicidad
Prevention of New Sensitization by Specific Immunotherapy
of 5, 50, 500, and 5 000 therapeutic units per milliliter. The
induction phase was performed according to the manufacturer’s
recommendations and was followed by a perennial schedule
with maintenance injections (0.8 mL, the maximum individual
dose tolerated by all patients at 4-week intervals).
The patients in the SIT-aq group were given treatment with
aqueous extracts prepared from solutions of 5000 allergy units
(AU) per milliliter (Greer Laboratories, Lenoir, North Carolina,
USA). Dilutions were prepared for concentrations of 1, 10, 100,
1000, 5000 AU/mL and given at weekly intervals for 5 years.
Dosages were adjusted on an individual basis. Specifically,
injections were postponed if other diseases were present and
the dose was lowered to the preceding dose at the next visit if
a local reaction greater than 3 cm in diameter appeared or it
was halved if a systemic reaction occurred. Patients were kept
under observation for 30 minutes after each administration.
87
regularly taken antihistamines (oral or nasal) counted 1 point,
topical corticosteroids counted 2 points, and requirement of
both topical steroid and antihistamines counted 3 points.
St at ist ical Analysis
All data were analyzed using a standard statistical software
package (SPSS for Windows, version 11.0). A χ2 test was
used for the comparison of groups in terms of sex, diagnosis,
and the development of new sensitization. One-way analysis
of variance was used for comparison of age groups. The
correlation between development of new sensitization and
atopy scores or medication scores of rhinitis and asthma
was analyzed with a Mann–Whitney U test. Changes within
each treatment group were tested using a Wilcoxon signed
rank test. A P value less than .05 was considered statistically
significant.
Environment al Avoidance M easures
All patients were instructed to take standard environmental
measures to decrease exposure to mites (ie, removal of carpets,
soft toys and plants from the patient’s bedroom, frequent
vacuum cleaning, washing sheets with water >55-60⬚ C at
least once a week, no use of humidifiers). Although mattress
encasings were recommended to all patients, they were too
expensive for the patients to acquire.
Drugs
For control of symptoms related to asthma and/or rhinitis,
all patients, whether undergoing SIT or not, were treated
according to the guidelines of the Global Initiative for
Asthma [18], the consensus statement of the EAACI for
allergic rhinitis [20], or the Allergic Rhinitis and Its Impact
on Asthma workshop report [21].
At opy Scores, M edicat ion Scores of Ast hma
and Rhinit is
Atopy scores were evaluated at the beginning and after 5
years of treatment in all patients according to skin prick test
results in the following way: a) the atopy score was negative
if the result of the skin prick test was not different from the
negative control; and b) it was assessed as 1+, 2+, 3+, or 4+ if
the wheal diameter was equal to 25 %, 50 %, 100 %, or 200 %
of the size of the histamine wheal. The total atopy score of the
patient was calculated as the sum of the positive results for
D pteronyssinus and D farinae.
All patients, whether treated with SIT or not, were seen
regularly and their required medication was recorded by a
medication score modified according to the system of Bousquet
et al [22]. For asthma, taking inhaled salbutamol 200 µg/day
counted 1 point, and regular use or 600 µg/day counted 2
points; inhaled cromolyn or nedocromil or oral ketotifen
counted 3 points; and inhaled steroids counted 4 points
(200-400 µg/day) or 5 points (400-800 µg/day). For rhinitis,
© 2007 Esmon Publicidad
Results
Pat ient s
There was no statistically significant difference between
groups in terms of age (P = .07) or sex (P = .473). Demographic
data of all patients are shown in Table 1. No statistically
significant difference between the groups was detected with
regard to diagnosis of asthma and/or rhinitis upon enrollment
(P = .984).
Development of New Sensit izat ions
At the end of 5 years, 64 out of 85 (75.3 %) children in the
SIT group showed no new sensitization, compared to 29 out of
62 children (46.7 %) in the control group (P = .002). There was no
statistically significant difference between the SIT-aq and SIT-ad
subgroups in terms of development of new sensitization (P = .605).
The risk of development of new sensitization was 3-fold higher
in the control group than in the SIT-aq group (95 % confidence
interval [CI], 1.28-7.04; P = .012) and 4-fold higher in the control
group than in the SIT-ad group (95 % CI, 1.68-9.43; P = .002). In
the SIT group overall, 15 out of the 21 patients developing at least
1 new sensitization developed only 1 and 6 patients developed
2 or more new sensitizations; in the control group, on the other
hand, 1 new sensitization was seen in 22 out of 33 patients and
2 or more new sensitizations were seen in 11 patients at the end
of 5 years. The most frequent new sensitizations at the end of
the study were to grass pollens. The next most frequent were to
animal danders and olive pollens (Table 2).
There was a statistically significant correlation between
the development of new sensitizations and final atopy scores
(P = .002), final medication scores of rhinitis (P = .008),
and asthma (P = .013) evaluated after 5 years of treatment.
The patients developing new sensitivities had higher atopy
scores and medication scores for both rhinitis and asthma in
comparison to patients not developing new sensitizations after
5 years of treatment.
J Investig Allergol Clin Immunol 2007; Vol. 17(2): 85-91
88
Table 1. Patient Characteristics Over a Period of 5 Years*
SIT Group
SIT, Adsorbed Extracts
SIT, Aqueous Extracts
Control Group
45
23/22
13.88 ± 2.81
21 (46.7%)
19 (42.2%)
5 (11.1%)
40
23/17
14.95 ± 2.75
18 (45%)
18 (45%)
4 (10%)
62
28/34
13.5 ± 3.56
26 (41.9%)
28 (45.2%)
8 (12.9%)
35 (77.7%)
29 (72.5%)
29 (46.7%)
No. of patients
Gender, female/male
Age, y
Asthma, n (%)
Asthma and rhinitis, n (%)
Rhinitis, n (%)
Patients with no new
sensitizations at the end
of the study, n (%)
* Data are mean ± SD unless otherwise indicated.
Table 2. Distribution of New Sensitizations Developed in the Study Groups*
Total None Grass
Dog
Cat
Olive Pine
Cladosporium
species
Alternaria
species
Cockroach
Eucalyptus
SIT group
SIT-ad
SIT-aq
85
45
40
64
35
29
4
4
0
2
1
2
4
3
1
4
2
1
0
1
0
0
0
0
Control
group
62
29
12
12
9
3
3
0
1
2
1
* SIT-ad indicates specifi c immunotherapy with adsorbed extracts; SIT-aq, with aqueous extracts.
Patients who underwent SIT who developed new sensitization
after 5 years tended to have higher atopy scores (5.52 ± 1.75)
at the beginning when compared to patients who were still
monosensitized at the end of the study (4.70 ± 2.04), although
this difference was not statistically significant (P = .103).
We found no correlation between the onset of new
sensitizations and diagnosis (rhinitis and/or asthma)
(P = .610).
for atopy scores (P = .357) or medication scores for rhinitis
(P = .298) in the SIT-aq group after 5 years. There was no
significant difference in the medication scores for rhinitis
(P = .421) or asthma (P = .818) in the control group after 5
years of treatment, whereas atopy scores were found to be
significantly increased (P = .008) (Figure 1).
Progression From Rhinit is t o Ast hma
At opy Scores and M edicat ion Scores
f or Ast hma and Rhinit is
Atopy scores and medication scores of rhinitis and
asthma of all patients are shown in Figures 1 and 2. Five
years of SIT with adsorbed extracts led to a significant
improvement in atopy scores (P = .05) (Figure 1) and
medication scores for asthma (P = .001) (Figure 2);
decreased drug intake for relief of rhinitis symptoms was
observed in the SIT-ad group, but it was not statistically
significant (P = .167). In the SIT-aq group, there was significant
improvement only in the medication scores for asthma (P = .004)
(Figure 2). We found no statistically significant difference
J Investig Allergol Clin Immunol 2007; Vol. 17(2): 85-91
The 5 patients having only rhinitis in the SIT-ad group did
not develop asthma during the 5 years of the treatment. Two
of the 4 patients in the SIT-aq group and 4 of the 10 patients
in the control group who had only rhinitis developed asthma
in the second and third years of treatment.
Discussion
In the present study, 85 children with asthma and/or
rhinitis aged between 6 and 16 years, monosensitized to
house dust mite, received SIT for 5 years with adsorbed or
aqueous extracts and were evaluated and compared with 62
© 2007 Esmon Publicidad
Prevention of New Sensitization by Specific Immunotherapy
P = .05
6
89
P = .008
Atopy Score
5
4
3
2
1
0
SIT-ad Group
SIT-aq Group
Control
Final Score
First Score
4
P = .001
Figure 1. Atopy scores. Specifi c immunotherapy (SIT)
with adsorbed extracts (SIT-ad) reduced atopy scores
signifi cantly whereas the atopy scores of the control
group increased after 5 years of treatment. SIT-aq
indicates SIT with aqueous extracts.
P = .004
3
Medication Score
3
2
2
1
1
0
SIT-ad Group
SIT-aq Group
First Score
Final Score
children monosensitized to house dust mite who received
only pharmacologic treatment. The comparison was based
on the development of new sensitization. New sensitizations
to inhalant allergens developed less frequently (24.7 %) in
children who received SIT than those who did not (53.3 %).
The patients developing new sensitizations had higher atopy
scores and medication scores of rhinitis and asthma than did
those who did not develop new sensitizations.
Allergen-specific immunotherapy has been widely used
for many years. The efficacy and long term effect of SIT in
reducing symptoms, medication, and bronchial reactivity have
been well established [4-13]. It has been less well documented
that SIT with a single allergen has a preventive effect against
sensitization to different inhalant allergens [14-17]. Previously,
2 studies were carried out on a pediatric population allergic to
house dust mite [14,15]. In a double-blind placebo-controlled
trial, 10 out of 22 children monosensitized to house dust mite
in the active treatment group developed new sensitization as
compared to all children in the control group [14]. In another
trial in children sensitive to house dust mite, 24.6 % of patients
treated with SIT for 3 years developed a new sensitization in
comparison to 66.7 % of children in the control group [15]. In a
© 2007 Esmon Publicidad
Control
Figure 2. Medication score of asthma. Specifi c
immunotherapy with adsorbed (SIT-ad) and aqueous
(SIT-aq) extracts reduced the asthma medication score
signifi cantly after 5 years of treatment.
retrospective study of pollen- or mite-sensitive adults, the rate
of new sensitizations developing after 4 years of SIT was found
to be 23.75 % in comparison to 68.03 % in the control group
[16]. In our study the prevalence of new sensitizations in the
SIT group was consistent with the findings from those studies,
but the rate in our control group was lower. A single study
reported that SIT did not exert any preventive effect against
de novo sensitization to airborne allergens in monosensitized
adult patients [23]. In that study, the author suggested that
genetic predisposition of an individual towards developing a
type 2 helper T cell (TH2) response to specific allergens is a key
determinant in the development of new sensitization.
Some longitudinal studies have reported an increase in the
sensitization rate from childhood to adulthood [24-26]. One of
them was carried out on children and concluded that the evolution
from mono- to polysensitization was age-related [25]. In another
study the same authors reported that the rate of development
of polysensitization was 43.6 % in previously monosensitized
children after 2 to 10 years from the first diagnosis [26]. They
found that 45.4% of the patients who were monosensitized to
house dust mite became polysensitized. We found a slightly higher
rate of polysensitization (53.3 %) in our control group.
J Investig Allergol Clin Immunol 2007; Vol. 17(2): 85-91
90
Our observation that patients developing new sensitizations
also have higher atopy scores than those who did not develop
new sensitizations supports the probability that genetic
predisposition influences the onset of new sensitizations.
Additionally, although it was not statistically significant, the
atopy scores of the patients who developed new sensitization in
the SIT-group were higher than those who did not. Therefore,
transition from mono- to polysensitization is inevitable as
the child grows toward adulthood. Nevertheless, we also
demonstrated that SIT, especially with adsorbed extracts, has a
significant effect on both the development of new sensitizations
(77.7 %) and decreasing atopy scores. We suggest that SIT
has a significant preventive effect on the development of
new sensitizations in children monosensitized to house dust
mite, but our interpretation is that such therapy is able to
decrease the absolute rate but not the normal trend towards
new sensitizations.
The mechanisms that explain the lower rate of new
sensitizations in children given SIT are unclear. It has been
reported that SIT has an effect on the regulation of the balance
between TH1 and TH2 cells [27] and has been shown to
decrease the production of interleukin (IL) 4 and IL-5 [28,29],
increase the production of interferon-γ [30], and decrease the
number of inflammatory cells in the nose [31]. The induction
of peripheral T-cell tolerance plays a crucial role in SIT and
is initiated by the action of IL-10 and tumor growth factor ß,
which are increasingly produced by antigen-specific regulatory
T cells. Tolerance to the allergen and the development of
a state of specific anergy in peripheral T cells by IL-10 are
important immunological changes associated with SIT [32].
It was suggested that these actions may modify or at least
delay the natural course of respiratory allergic diseases. In
our opinion, these SIT-related modifications of peripheral and
mucosal TH2 responses to allergens in favor of TH1 responses
may contribute significantly to preventing the development
of new sensitizations in patients who are monosensitized to
house dust mite.
One study reported that new sensitizations were significantly
more likely to occur in patients suffering from asthma and
rhinitis as compared to patients with only rhinitis [16].
Our results are not consistent with this report; we found no
correlation between the development of new sensitizations and
diagnosis. This discrepancy may be related to the small number
of the patients with only rhinitis in our study.
A limitation of our study is that it was not a randomized
or placebo-controlled trial. However, our aim was primarily
to explore whether SIT had the potential to reduce the
development of new sensitizations by using an objective
parameter, namely skin prick testing. A strength of our study
is that data from a large sample of patients were analyzed and
both SIT and non-SIT groups had homogenous distributions
with respect to gender, age, and diagnosis. Furthermore, to
our knowledge, this is the first study to compare SIT with
aqueous extracts to SIT with adsorbed extracts with regard
to the development of new sensitizations. In comparison to
the control group, SIT with both extracts had a significant
preventive effect on the onset of new sensitizations and led
to a reduction of asthma medication scores in monosensitized
patients.
J Investig Allergol Clin Immunol 2007; Vol. 17(2): 85-91
We believe that SIT should begin at earlier ages, especially
in children with rhinitis who are monosensitized to house dust
mite to prevent polysensitization. We also suggest that adsorbed
extracts should be preferred to aqueous ones because of the
greater preventive effect on the development of new sensitization,
decreased number of injections, and earlier achievement of
maintenance. Further investigation is required to clarify the
immunologic mechanisms by which SIT reduces the development
of new sensitizations in monosensitized children.
References
1. Noon L. Prophylactic inoculation against hay fever. Lancet.
1911;1:1572-3.
2. Bousquet J, Lockey RF, Malling HJ. WHO Position Paper. Allergen
immunotherapy: therapeutical vaccines for allergic diseases.
Allergy. 1998;53(Suppl 44):1-42.
3. Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E, Bjorksten B,
Bousquet J, Caillot D, Canonica GW, Passalacqua G, SaxonisPapageorgiou P, Valovirta E.. Local Immunotherapy. Position
paper by the working group on local Immunotherapy of
the EAACI Subcommittee and the ESPACI Immunotherapy
Subcommittee. Allergy. 1998;53:933-44.
4. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy
effective in asthma? A meta-analysis of randomized controlled
trials. Am J Respir Crit Care Med. 1995;151:969-74.
5. Rak S, Lowhagen O, Venge P. The effect of immunotherapy on
bronchial hyperresponsiveness and eosinophil cationic protein in
pollen allergic patients. J Allergy Clin Immunol. 1988;82:470-80.
6. Pichler CE, Helbling A, Pichler WJ. Three years of specifi c
immunotherapy with house-dust-mite extracts in patients
with rhinitis and asthma: signifi cant improvement of allergenspecifi c parameters and of nonspecifi c bronchial hyperreactivity.
Allergy. 2001;56:301-6.
7. Pifferi M, Baldini G, Marrazzini G, Baldini M, Ragazzo V, Pietrobelli
A, Boner AL.. Benefi ts of immunotherapy with a standardized
Dermatophagoides pteronyssinus extract in asthmatic children:
a three-year prospective study. Allergy. 2002;57:785-90.
8. Ameal A, Vega-Chicote JM, Fernandez S, Miranda A, Carmona
MJ, Rondon MC, Reina E, Garcia-Gonzalez JJ.. Double-blind
and placebo-controlled study to assess effi cacy and safety of a
modifi ed allergen extract of Dermatophagoides pteronyssinus in
allergic asthma. Allergy. 2005;60:1178-83.
9. Wang H, Lin X, Hao C, Zhang C, Sun B, Zheng J, Chen P, Sheng
J, Wu A, Zhong N.. A double-blind, placebo-controlled study of
house dust mite immunotherapy in Chinese asthmatic patients.
Allergy. 2006;61:191-7.
10. Clavel R, Bousquet J, Andre C. Clinical effi cacy of sublingualswallow immunotherapy: a double-blind, placebo-controlled
trial of a standardized fi ve-grass-pollen extract in rhinitis.
Allergy. 1998;53:493-8.
11. Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C,
Mela GS, Canonica GW.. Randomized controlled trial of local
allergoid immunotherapy on allergic infl ammation in miteinduced rhinoconjunctivitis. Lancet. 1998;351:629-32.
12. Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of
specifi c immunotherapy in patients with severe perennial
© 2007 Esmon Publicidad
Prevention of New Sensitization by Specific Immunotherapy
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
allergic rhinitis induced by house-dust mite: a doubleblind, randomized, placebo-controlled trial. Clin Exp Allergy.
2003;33:1076-82.
Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen
L, Koivikko A, Koller DY, Niggemann B, Norberg LA, Urbanek
R, Valovirta E, Wahn U. Pollen immunotherapy reduces
the development of asthma in children with seasonal
rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol.
2002;109:251-6.
Des Roches A, Paradis L, Menardo JL, Bouges S, Daures
JP, Bousquet J. Immunotherapy with a standardized
Dermatophagoides pteronyssinus extract. VI. Specifi c
immunotherapy prevents the onset of new sensitizations in
children. J Allergy Clin Immunol. 1997;99:450-3.
Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S.
Prevention of new sensitizations in asthmatic children
monosensitized to house dust mite by specifi c immunotherapy.
A six-year follow-up study. Clin Exp Allergy. 2001;31:1392-7.
Purello-D’Ambrosio F, Gangemi S, Merendino RA, Isola
S, Puccinelli P, Parmiani S, Ricciardi L.. Prevention of new
sensitizations in monosensitized subjects submitted to specifi c
immunotherapy or not. A retrospective study. Clin Exp Allergy.
2001;31:1295-1302.
Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year
follow-up after discontinuation of preseasonal grass pollen
immunotherapy in childhood. Allergy. 2006;61:198-201.
Global Initiative for Asthma. Global Strategy for Asthma
Management and Prevention: NHLBI/WHO Workshop Report,
publication number 95-3659. Bethesda MD: National Institute
of Health and National Heart, Lung and Blood Institute, 1995.
Dreborg S, Frew AJ. Allergen standardization and skin tests.
EAACI Position Paper. Allergy. 1993;48(Suppl14):49-82.
van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J,
Canonica GW, Durham SR, Fokkens WJ, Howarth PH, Lund
V, Malling HJ, Mygind N, Passali D, Scadding GK, Wang DY..
Consensus statement on the treatment of allergic rhinitis.
EAACI. Allergy. 2000;55:116-34.
Bousquet J, van Cauwenberge P, Khaltaev N and in collaboration
with the WHO. ARIA Workshop report. J Allergy Clin Immunol.
2001;108: S147-334.
Bousquet J, Guerin B, Dotte A, Dhivert H, Djoukhadar F, Hewitt
B, Michel FB.. Comparison between rush immunotherapy with
a standardized allergen and an alum adjuved pyridine extracted
material in grass pollen allergy. Clinical Allergy. 1985;15:17993.
Asero R. Injection immunotherapy with different airborne
allergens did not prevent de novo sensitization to ragweed
and birch pollen north of Milan. Int Arch Allergy Immunol.
2004;133:49-54.
© 2007 Esmon Publicidad
91
24. Barbee RA, Kaltenborn W, Lebowitz MD, Burrows B. Longitudinal
changes in allergen skin test reactivity in a community
population sample. J Allergy Clin Immunol. 1987;79:16-24.
25. Silvestri M, Oddera S, Rossi GA, Crimi P. Sensitization to
airborne allergens in children with respiratory symptoms. Ann
Allergy Asthma Immunol. 1996;76:239-44.
26. Silvestri M, Rossi GA, Cozzani S, Pulvirenti G, Fasce L. Agedependent tendency to become sensitized to other classes of
aeroallergens in atopic asthmatic children. Ann Allergy Asthma
Immunol. 1999;83:335-40.
27. Durham SR, Till SJ. Immunologic changes associated with
allergen immunotherapy. JAllergy Clin Immunol. 1998;102:15764.
28. Akoum H, Tsicopoulos A, Vorng H, Wallaert B, Dessaint JP,
Joseph M, Hamid Q, Tonnel AB.. Venom immunotherapy
modulates interleukin-4 and interferon-gamma messenger
RNA expression of peripheral T lymphocytes. Immunology.
1996;87:593-8.
29. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen
immunotherapy decreases interleukin 4 production in CD4+ T
cells from allergic individuals. J Exp Med. 1993;178:2123-30.
30. Jutel M , Pichler WJ, Skrbic D, Urw yler A, Dahinden C, M uller
UR. Bee venom immunotherapy results in a decrease
of IL-4 and IL-5 and increase of IFN-gamma secretion in
specific allergen-stimulated T cell cultures. J Immunol.
1995;154:4187-94.
31. Lack G, Nelson HS, Amran D, Oshiba A, Jung T, Bradley KL,
Giclas PC, Gelfand EW. Rush immunotherapy results in allergenspecifi c alterations in lymphocyte function and interferon
gamma production in CD4+ T cells. J Allergy Clin Immunol.
1997;99:530-8.
32. Akdis CA, Blaser K. Immunologic mechanisms of specifi c
immunotherapy. Allergy. 1999;54(Suppl56):31-2.
❚ M anuscript received July 27, 2006; accept ed f or publicat ion Oct ober 24, 2006
❚
Ayfer Inal
Division of Pediatric Allergy and Immunology
Çukurova University Faculty of Medicine
Balcal1 Hospital
01330, Adana, Turkey
E-mail: ainal@cu.edu.tr
J Investig Allergol Clin Immunol 2007; Vol. 17(2): 85-91